{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T10:06:47Z","timestamp":1773482807316,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,8,27]],"date-time":"2015-08-27T00:00:00Z","timestamp":1440633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,8,27]],"date-time":"2015-08-27T00:00:00Z","timestamp":1440633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinson's Disease"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background:<\/jats:title>\n                <jats:p>The concept of differing clinical phenotypes within Parkinson\u2019s disease (PD) is well represented in the literature. However, there is no consensus as to whether any particular disease phenotype is associated with an increased risk of mild cognitive impairment (MCI) using the newly proposed Movement Disorders Society diagnostic criteria for this feature.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>AIMS:<\/jats:title>\n                <jats:p>To explore the expression of PD-MCI in relation to the heterogeneity of idiopathic PD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods:<\/jats:title>\n                <jats:p>A cluster analysis incorporating a range of specific demographic, clinical and cognitive variables was performed on 209 patients in the early stages of PD (between Hoehn and Yahr stages I\u2013III). <jats:italic>Post hoc<\/jats:italic> analyses exploring variables not included in the clustering solution were performed to interrogate the veracity of the subgroups generated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results:<\/jats:title>\n                <jats:p>This study identified four distinct PD cohorts: a younger disease-onset subgroup, a tremor dominant subgroup, a non-tremor dominant subgroup, and a subgroup with rapid disease progression. The present study identified a differential expression of PD-MCI across these subgroups, with the highest frequency observed in the non-tremor dominant cluster. The non-tremor dominant subgroup was also associated with a higher prevalence of freezing of gait, hallucinations, daytime somnolence, and rapid eye movement sleep behavior disorder compared with other subgroups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions:<\/jats:title>\n                <jats:p>This study confirms the existence of heterogeneity within the early clinical stages of PD and for the first time highlights the differential expression of PD-MCI using the newly defined diagnostic criteria for this feature. An improved understanding of PD-MCI and its clinical relationships may lead to an improved understanding of the pathophysiology underlying heterogeneity in PD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/npjparkd.2015.15","type":"journal-article","created":{"date-parts":[[2015,8,27]],"date-time":"2015-08-27T15:30:30Z","timestamp":1440689430000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["The relationships between mild cognitive impairment and phenotype in Parkinson\u2019s disease"],"prefix":"10.1038","volume":"1","author":[{"given":"Jennifer YY","family":"Szeto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"O\u2019Callaghan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M","family":"Shine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0835-2310","authenticated-orcid":false,"given":"Courtney C","family":"Walton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loren","family":"Mowszowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon L","family":"Naismith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0422-8398","authenticated-orcid":false,"given":"Glenda M","family":"Halliday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon JG","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,27]]},"reference":[{"key":"BFnpjparkd201515_CR1","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jocn.2008.08.020","volume":"16","author":"SJG Lewis","year":"2009","unstructured":"Lewis SJG, Barker RA . Understanding the dopaminergic deficits in Parkinson\u2019s disease: Insights into disease heterogeneity. J Clin Neurosci 2009; 16: 620\u2013625.","journal-title":"J Clin Neurosci"},{"key":"BFnpjparkd201515_CR2","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/mds.25857","volume":"29","author":"GM Halliday","year":"2014","unstructured":"Halliday GM, Leverenz JB, Schneider JS, Adler CH . The neurobiological basis of cognitive impairment in Parkinson\u2019s disease. Mov Disord 2014; 29: 634\u2013650.","journal-title":"Mov Disord"},{"key":"BFnpjparkd201515_CR3","doi-asserted-by":"publisher","first-page":"e6507","DOI":"10.1371\/journal.pone.0006507","volume":"4","author":"S Kroener","year":"2009","unstructured":"Kroener S, Chandler LJ, Phillips PE, Seamans JK . Dopamine modulates persistent synaptic activity and enhances the signal-to-noise ratio in the prefrontal cortex. PLoS One 2009; 4: e6507.","journal-title":"PLoS One"},{"key":"BFnpjparkd201515_CR4","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/brain\/awm111","volume":"130","author":"CH Williams-Gray","year":"2007","unstructured":"Williams-Gray CH, Foltynie T, Brayne CEG, Robbins TW, Barker RA . Evolution of cognitive dysfunction in an incident Parkinson\u2019s disease cohort. Brain 2007; 130: 1787\u20131798.","journal-title":"Brain"},{"key":"BFnpjparkd201515_CR5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.24893","volume":"27","author":"I Litvan","year":"2012","unstructured":"Litvan I, Goldman JG, Tr\u00f6ster AI, Schmand BA, Weintraub D, Petersen RC et al. Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012; 27: 349\u2013356.","journal-title":"Mov Disord"},{"key":"BFnpjparkd201515_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1136\/jnnp.2003.033530","volume":"76","author":"SJG Lewis","year":"2005","unstructured":"Lewis SJG, Foltynie T, Blackwell AD, Robbins TW, Owen AM, Barker RA . Heterogeneity of Parkinson\u2019s disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 2005; 76: 343\u2013348.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFnpjparkd201515_CR7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.parkreldis.2008.09.003","volume":"15","author":"J Reijnders","year":"2009","unstructured":"Reijnders J, Ehrt U, Lousberg R, Aarsland D, Leentjens AFG . The association between motor subtypes and psychopathology in Parkinson\u2019s disease. Parkinsonism Relat Disord 2009; 15: 379\u2013382.","journal-title":"Parkinsonism Relat Disord"},{"key":"BFnpjparkd201515_CR8","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1093\/brain\/awp234","volume":"132","author":"M Selikhova","year":"2009","unstructured":"Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ . A clinico-pathological study of subtypes in Parkinson\u2019s disease. Brain 2009; 132: 2947\u20132957.","journal-title":"Brain"},{"key":"BFnpjparkd201515_CR9","doi-asserted-by":"publisher","first-page":"s77","DOI":"10.1007\/s100720200078","volume":"23","author":"E Gasparoli","year":"2002","unstructured":"Gasparoli E, Delibori D, Polesello G, Santelli L, Ermani M, Battistin L et al. Clinical predictors in Parkinson\u2019s disease. Neurol Sci 2002; 23: s77\u2013s78.","journal-title":"Neurol Sci"},{"key":"BFnpjparkd201515_CR10","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1136\/jnnp-2011-301874","volume":"83","author":"M Poletti","year":"2012","unstructured":"Poletti M, Frosini D, Pagni C, Baldacci F, Nicoletti V, Tognoni G et al. Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 2012; 83: 601\u2013606.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFnpjparkd201515_CR11","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1007\/s00415-008-0782-1","volume":"255","author":"B Post","year":"2008","unstructured":"Post B, Speelman JD, De Haan RJ . Clinical heterogeneity in newly diagnosed Parkinson\u2019s disease. J Neurol 2008; 255: 716\u2013722.","journal-title":"J Neurol"},{"key":"BFnpjparkd201515_CR12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1017\/S1355617798002859","volume":"4","author":"HL Katzen","year":"1998","unstructured":"Katzen HL, Levin BE, Llabre ML . Age of disease onset influences cognition in Parkinson\u2019s disease. J Int Neuropsychol Soc 1998; 4: 285\u2013290.","journal-title":"J Int Neuropsychol Soc"},{"key":"BFnpjparkd201515_CR13","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/WNL.29.9_Part_1.1253","volume":"29","author":"RP Lesser","year":"1979","unstructured":"Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barrett RE . Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 1979; 29: 1253\u20131253.","journal-title":"Neurology"},{"key":"BFnpjparkd201515_CR14","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/WCO.0000000000000112","volume":"27","author":"JG Goldman","year":"2014","unstructured":"Goldman JG, Postuma R . Premotor and nonmotor features of Parkinson\u2019s disease. Curr Opin Neurol 2014; 27: 434\u2013441.","journal-title":"Curr Opin Neurol"},{"key":"BFnpjparkd201515_CR15","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1002\/mds.21844","volume":"22","author":"B Dubois","year":"2007","unstructured":"Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA et al. Diagnostic procedures for Parkinson\u2019s disease dementia: recommendations from the movement disorder society task force. Mov Disord 2007; 22: 2314\u20132324.","journal-title":"Mov Disord"},{"key":"BFnpjparkd201515_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.parkreldis.2014.10.020","volume":"21","author":"JYY Szeto","year":"2015","unstructured":"Szeto JYY, Mowszowski L, Gilat M, Walton CC, Naismith SL, Lewis SJ . Assessing the utility of the Movement Disorder Society Task Force Level 1 diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease. Parkinsonism Relat Disord 2015; 21: 31\u201335.","journal-title":"Parkinsonism Relat Disord"},{"key":"BFnpjparkd201515_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1046\/j.1365-2869.2000.00177.x","volume":"9","author":"MW Johns","year":"2000","unstructured":"Johns MW . Sensitivity and specificity of the multiple sleep latency test (MSLT), the maintenance of wakefulness test and the Epworth sleepiness scale: failure of the MSLT as a gold standard. J Sleep Res 2000; 9: 5\u201311.","journal-title":"J Sleep Res"},{"key":"BFnpjparkd201515_CR18","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/sleep\/26.8.1049","volume":"26","author":"J Marinus","year":"2003","unstructured":"Marinus J, Visser M, van Hilten JJ, Lammers GJ, Stiggelbout AM . Assessment of sleep and sleepiness in Parkinson disease. Sleep 2003; 26: 1049\u20131054.","journal-title":"Sleep"},{"key":"BFnpjparkd201515_CR19","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1002\/mds.21740","volume":"22","author":"K Stiasny-Kolster","year":"2007","unstructured":"Stiasny-Kolster K, Mayer G, Sch\u00e4fer S, M\u00f6ller JC, Heinzel-Gutenbrunner M, Oertel WH . The REM sleep behavior disorder screening questionnaire\u2014a new diagnostic instrument. Mov Disord 2007; 22: 2386\u20132393.","journal-title":"Mov Disord"},{"key":"BFnpjparkd201515_CR20","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1136\/jnnp-2013-305021","volume":"84","author":"C Tremblay","year":"2013","unstructured":"Tremblay C, Achim AM, Macoir J, Monetta L . The heterogeneity of cognitive symptoms in Parkinson\u2019s disease: a meta-analysis. J Neurol Neurosurg Psychiatry 2013; 84: 1265\u20131272.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFnpjparkd201515_CR21","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00702-006-0518-2","volume":"114","author":"J Spiegel","year":"2007","unstructured":"Spiegel J, Hellwig D, Samnick S, Jost W, M\u00f6llers M-O, Fassbender K et al. Striatal FP-CIT uptake differs in the subtypes of early Parkinson\u2019s disease. J Neural Transm 2007; 114: 331\u2013335.","journal-title":"J Neural Transm"},{"key":"BFnpjparkd201515_CR22","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1093\/brain\/awp245","volume":"132","author":"CH Williams-Gray","year":"2009","unstructured":"Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW et al. The distinct cognitive syndromes of Parkinson\u2019s disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009; 132: 2958\u20132969.","journal-title":"Brain"},{"key":"BFnpjparkd201515_CR23","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1136\/jnnp-2013-305277","volume":"84","author":"CH Williams-Gray","year":"2013","unstructured":"Williams-Gray CH, Mason SL, Evans JR, Foltynie T, Brayne C, Robbins TW et al. The CamPaIGN study of Parkinson\u2019s disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 2013; 84: 1258\u20131264.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFnpjparkd201515_CR24","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.bbr.2009.12.048","volume":"221","author":"NI Bohnen","year":"2011","unstructured":"Bohnen NI, Albin RL . The cholinergic system and Parkinson disease. Behav Brain Res 2011; 221: 564\u2013573.","journal-title":"Behav Brain Res"},{"key":"BFnpjparkd201515_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/fnsys.2011.00031","volume":"5","author":"C Delaville","year":"2011","unstructured":"Delaville C, De Deurwaerd\u00e8re P, Benazzouz A . Noradrenaline and Parkinson\u2019s disease. Front Syst Neurosci 2011; 5: 31.","journal-title":"Front Syst Neurosci"},{"key":"BFnpjparkd201515_CR26","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1093\/brain\/awu193","volume":"137","author":"H Hall","year":"2014","unstructured":"Hall H, Reyes S, Landeck N, Bye C, Leanza G, Double K et al. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson\u2019s disease. Brain 2014; 137: 2493\u20132508.","journal-title":"Brain"},{"key":"BFnpjparkd201515_CR27","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s00415-005-0971-0","volume":"253","author":"NI Bohnen","year":"2006","unstructured":"Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Constantine GM et al. Cognitive correlates of cortical cholinergic denervation in Parkinson\u2019s disease and Parkinsonian dementia. J Neurol 2006; 253: 242\u2013247.","journal-title":"J Neurol"},{"key":"BFnpjparkd201515_CR28","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1093\/brain\/115.6.1701","volume":"115","author":"JA Cooper","year":"1992","unstructured":"Cooper JA, Sagar HJ, Doherty SM, Jordan N, Tidswell P, Sullivan EV . Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease: a follow-up study of untreated patients. Brain 1992; 115: 1701\u20131725.","journal-title":"Brain"},{"key":"BFnpjparkd201515_CR29","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1006\/brcg.1999.1083","volume":"40","author":"M-A B\u00e9dard","year":"1999","unstructured":"B\u00e9dard M-A, Pillon B, Dubois B, Duchesne N, Masson H, Agid Y . Acute and long-term administration of anticholinergics in Parkinson\u2019s disease: specific effects on the subcortico-frontal syndrome. Brain Cogn 1999; 40: 289\u2013313.","journal-title":"Brain Cogn"},{"key":"BFnpjparkd201515_CR30","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.parkreldis.2014.02.028","volume":"20","author":"JM Hall","year":"2014","unstructured":"Hall JM, Shine JM, Walton CC, Gilat M, Kamsma YPT, Naismith SL et al. Early phenotypic differences between Parkinson\u2019s disease patients with and without freezing of gait. Parkinsonism Relat Disord 2014; 20: 604\u2013607.","journal-title":"Parkinsonism Relat Disord"},{"key":"BFnpjparkd201515_CR31","doi-asserted-by":"crossref","unstructured":"Lewis SJ, Shine JM . The next step: a common neural mechanism for freezing of gait. Neuroscientist 2014, 1\u201311.","DOI":"10.1177\/1073858414559101"},{"key":"BFnpjparkd201515_CR32","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/brain\/awf033","volume":"125","author":"AJ Harding","year":"2002","unstructured":"Harding AJ, Broe GA, Halliday GM . Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002; 125: 391\u2013403.","journal-title":"Brain"},{"key":"BFnpjparkd201515_CR33","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1185\/030079902125000813","volume":"18","author":"R Bullock","year":"2002","unstructured":"Bullock R, Cameron A . Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson\u2019s disease: a case series. Curr Med Res Opin 2002; 18: 258\u2013264.","journal-title":"Curr Med Res Opin"},{"key":"BFnpjparkd201515_CR34","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/npp.2009.176","volume":"35","author":"HY Meltzer","year":"2009","unstructured":"Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D et al. Pimavanserin, a serotonin2A receptor inverse agonist, for the treatment of Parkinson\u2019s disease psychosis. Neuropsychopharmacology 2009; 35: 881\u2013892.","journal-title":"Neuropsychopharmacology"},{"key":"BFnpjparkd201515_CR35","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/1531-8257(200101)16:1<135::AID-MDS1006>3.0.CO;2-Q","volume":"16","author":"SA Factor","year":"2001","unstructured":"Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeois K . Clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord 2001; 16: 135\u2013139.","journal-title":"Mov Disord"},{"key":"BFnpjparkd201515_CR36","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1136\/jnnp.2007.116830","volume":"79","author":"MD Gjerstad","year":"2008","unstructured":"Gjerstad MD, Boeve B, Wentzel-Larsen T, Aarsland D, Larsen JP . Occurrence and clinical correlates of REM sleep behaviour disorder in patients with Parkinson\u2019s disease over time. J Neurol Neurosurg Psychiatry 2008; 79: 387\u2013391.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFnpjparkd201515_CR37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2165\/11539720-000000000-00000","volume":"25","author":"B Knie","year":"2011","unstructured":"Knie B, Mitra MT, Logishetty K, Chaudhuri KR . Excessive daytime sleepiness in patients with Parkinson\u2019s disease. CNS Drugs 2011; 25: 203\u2013212.","journal-title":"CNS Drugs"},{"key":"BFnpjparkd201515_CR38","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jns.2009.08.021","volume":"289","author":"LT Grinberg","year":"2010","unstructured":"Grinberg LT, Rueb U, Alho AT, Heinsen H . Brainstem pathology and non-motor symptoms in PD. J Neurol Sci 2010; 289: 81\u201388.","journal-title":"J Neurol Sci"},{"key":"BFnpjparkd201515_CR39","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/mds.20719","volume":"21","author":"E Sinforiani","year":"2006","unstructured":"Sinforiani E, Zangaglia R, Manni R, Cristina S, Marchioni E, Nappi G et al. REM sleep behavior disorder, hallucinations, and cognitive impairment in Parkinson\u2019s disease. Mov Disord 2006; 21: 462\u2013466.","journal-title":"Mov Disord"},{"key":"BFnpjparkd201515_CR40","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1002\/mds.20582","volume":"20","author":"C Pacchetti","year":"2005","unstructured":"Pacchetti C, Manni R, Zangaglia R, Mancini F, Marchioni E, Tassorelli C et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson\u2019s disease. Mov Disord 2005; 20: 1439\u20131448.","journal-title":"Mov Disord"},{"key":"BFnpjparkd201515_CR41","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00702-014-1271-6","volume":"122","author":"CC Walton","year":"2015","unstructured":"Walton CC, Shine JM, Mowszowski L, Gilat M, Hall JM, O\u2019Callaghan C et al. Impaired cognitive control in Parkinson\u2019s disease patients with freezing of gait in response to cognitive load. J Neural Transm 2015; 122: 653\u2013660.","journal-title":"J Neural Transm"},{"key":"BFnpjparkd201515_CR42","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1136\/jnnp-2011-301818","volume":"83","author":"S Hirano","year":"2012","unstructured":"Hirano S, Shinotoh H, Eidelberg D . Functional brain imaging of cognitive dysfunction in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 2012; 83: 963\u2013969.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFnpjparkd201515_CR43","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1212\/WNL.0b013e31827b1a07","volume":"80","author":"SN Gomperts","year":"2013","unstructured":"Gomperts SN, Locascio JJ, Rentz D, Santarlasci A, Marquie M, Johnson KA et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 2013; 80: 85\u201391.","journal-title":"Neurology"},{"key":"BFnpjparkd201515_CR44","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/brain\/awr031","volume":"134","author":"Y Compta","year":"2011","unstructured":"Compta Y, Parkkinen L, O\u2019Sullivan SS, Vandrovcova J, Holton JL, Collins C et al. Lewy-and Alzheimer-type pathologies in Parkinson\u2019s disease dementia: which is more important? Brain 2011; 134: 1493\u20131505.","journal-title":"Brain"},{"key":"BFnpjparkd201515_CR45","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ana.21192","volume":"62","author":"A Goris","year":"2007","unstructured":"Goris A, Williams-Gray CH, Clark GR, Foltynie T, Lewis SJ, Brown J et al. Tau and \u03b1-synuclein in susceptibility to, and dementia in, Parkinson\u2019s disease. Ann Neurol 2007; 62: 145\u2013153.","journal-title":"Ann Neurol"},{"key":"BFnpjparkd201515_CR46","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/mds.20118","volume":"19","author":"T Foltynie","year":"2004","unstructured":"Foltynie T, Goldberg TE, Lewis SG, Blackwell AD, Kolachana BS, Weinberger DR et al. Planning ability in Parkinson\u2019s disease is influenced by the COMT val158met polymorphism. Mov Disord 2004; 19: 885\u2013891.","journal-title":"Mov Disord"},{"key":"BFnpjparkd201515_CR47","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/nan.12195","volume":"41","author":"H McCann","year":"2014","unstructured":"McCann H, McGeachie AB, Silberstein P, Lewis SJ, Halliday GM . Restricted disease propagation in multiple system atrophy with prolonged survival. Neuropathol Appl Neurobiol 2014; 41: 681\u2013685.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"BFnpjparkd201515_CR48","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1136\/jnnp.2010.232678","volume":"82","author":"WG Reid","year":"2011","unstructured":"Reid WG, Hely MA, Morris JG, Loy C, Halliday GM . Dementia in Parkinson\u2019s disease: a 20-year neuropsychological study (Sydney Multicentre Study). J Neurol Neurosurg Psychiatry 2011; 82: 1033\u20131037.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFnpjparkd201515_CR49","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1001\/jamaneurol.2013.4498","volume":"71","author":"RN Alcalay","year":"2014","unstructured":"Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M et al. Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. JAMA Neurol 2014; 71: 62\u201367.","journal-title":"JAMA Neurol"},{"key":"BFnpjparkd201515_CR50","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/jnnp.67.4.492","volume":"67","author":"D Aarsland","year":"1999","unstructured":"Aarsland D, Larsen JP, Lim NG, Janvin C, Karlsen K, Tandberg E et al. Range of neuropsychiatric disturbances in patients with Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 1999; 67: 492\u2013496.","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/npjparkd201515.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/npjparkd201515","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/npjparkd201515.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T12:57:27Z","timestamp":1672923447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/npjparkd201515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,27]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12,17]]}},"alternative-id":["BFnpjparkd201515"],"URL":"https:\/\/doi.org\/10.1038\/npjparkd.2015.15","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,27]]},"assertion":[{"value":"13 February 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15015"}}